{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:23:33Z","timestamp":1792167813442,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the factors influencing <jats:sup>131<\/jats:sup>I-refractory Graves\u2019 disease (GD) hyperthyroidism in patients, develop a nomogram prediction model, and conduct its validation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 272 hyperthyroidism patients who received initial <jats:sup>131<\/jats:sup>I treatment at our hospital from January 2021 to January 2022 were randomly selected. Patients were divided into refractory hyperthyroidism group (92 cases) and non-refractory hyperthyroidism group (180 cases) based on whether they were cured after one course of <jats:sup>131<\/jats:sup>I treatment. They were randomly divided into a training group (n=190) and an internal validation group (n=82) in a 7:3 ratio. Multiple factors that might affect the efficacy of <jats:sup>131<\/jats:sup>I treatment were collected, including 16 variables such as clinical characteristics, laboratory, and imaging examinations. LASSO regression was used for optimization and selection, and a multivariate logistic regression model was constructed to create a nomogram prediction model. The model\u2019s discrimination, calibration, and clinical validity were evaluated using the receiver operating characteristic (ROC) curve, Hosmer-Lemeshow calibration curve, and decision curve analysis (DCA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no statistically significant differences (P&amp;gt;0.05) in the comparison of the 16 variables between the training and validation groups. Following LASSO regression analysis, six predictive variables associated with <jats:sup>131<\/jats:sup>I-refractory hyperthyroidism were identified: the duration of hyperthyroidism, nighttime sleep quality, the presence of Graves' ophthalmopathy (GO), the effective half-life of thyroid <jats:sup>131<\/jats:sup>I, thyroid uptake <jats:sup>99m<\/jats:sup>Tc value, and thyroid mass. The area under the ROC curve (AUC) for the risk of <jats:sup>131<\/jats:sup>I refractory hyperthyroidism in the training group was 0.943 (95% CI: 0.909-0.977), and the AUC for the validation group was 0.926 (95% CI: 0.870-0.983). The Hosmer-Lemeshow calibration curve showed good fit (training group P=0.876; validation group P=0.202). DCA demonstrated that when the threshold probability for equal patients ranged from 0.04 to 0.86 in the training group and from 0.09 to 0.87 in the validation group, using the nomogram prediction model to predict the risk of refractory hyperthyroidism after <jats:sup>131<\/jats:sup>I treatment was more beneficial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study found that the duration of GD hyperthyroidism, nighttime sleep quality, GO, effective half-life of thyroid <jats:sup>131<\/jats:sup>I, thyroid uptake <jats:sup>99m<\/jats:sup>Tc value, and thyroid mass are independent influencing factors of <jats:sup>131<\/jats:sup>I refractoriness. A risk prediction model including these six factors was established. This model provides guidance for the diagnosis and treatment decisions of <jats:sup>131<\/jats:sup>I refractory GD hyperthyroidism, offers a quantitative tool for clinical assessment of <jats:sup>131<\/jats:sup>I efficacy, and aids in personalized treatment decisions, reducing the burden of ineffective or inefficient treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1628226","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:15:43Z","timestamp":1755058543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and validation of a nomogram prediction model for factors influencing 131I-refractory Graves\u2019 hyperthyroidism"],"prefix":"10.3389","volume":"16","author":[{"given":"Kehua","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhou","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00481","article-title":"Neuroendocrine whiplash: slamming the breaks on anabolic-androgenic steroids following repetitive mild traumatic brain injury in rats may worsen outcomes","volume":"10","author":"Tabor","year":"2019","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.23736\/S1824-4785.21.03337-9","article-title":"Radioiodine therapy of Graves\u2019 disease","volume":"65","author":"Piccardo","year":"2021","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06274-5","article-title":"The EANM guideline on radioiodine therapy of benign thyroid disease","volume":"50","author":"Campenn\u00ec","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"2018 European thyroid association guideline for the management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000288","article-title":"Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves\u2019 disease","volume":"348","author":"Liu","year":"2014","journal-title":"Am J Med Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10792-010-9368-x","article-title":"Association between radioiodine therapy for Graves\u2019 hyperthyroidism and thyroid-associated ophthalmopathy","volume":"30","author":"El-Kaissi","year":"2010","journal-title":"Int Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mbs.2018.06.004","article-title":"The Bayesian adaptive lasso regression","volume":"303","author":"Alhamzawi","year":"2018","journal-title":"Math Biosci"},{"key":"B9","article-title":"Factors affecting exclusive breastfeeding, using adaptive LASSO regression","volume":"6","author":"Maharlouei","year":"2018","journal-title":"Int J Community Based Nurs Midwifery"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180343","article-title":"Bayesian Lasso and multinomial logistic regression on GPU","volume":"12","author":"\u010ce\u0161novar","year":"2017","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2016.02.012","article-title":"Treatment failure prediction for head-and-neck cancer radiation therapy","volume":"20","author":"Rocha","year":"2016","journal-title":"Cancer Radiother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12967-022-03340-8","article-title":"A machine learning-based risk stratification tool for in-hospital mortality of intensive care unit patients with heart failure","volume":"20","author":"Luo","year":"2022","journal-title":"J Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01368-7","article-title":"Risk prediction models for myocardial dysfunction and heart failure in patients with current or prior cancer","volume":"25","author":"van Dalen","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2006.00178.x","article-title":"Understanding diagnostic tests 3: Receiver operating characteristic curves","volume":"96","author":"Akobeng","year":"2007","journal-title":"Acta Paediatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/sim.5525","article-title":"Standardizing the power of the Hosmer-Lemeshow goodness of fit test in large data sets","volume":"32","author":"Paul","year":"2013","journal-title":"Stat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11162244","article-title":"Optimizing clinical decision making with decision curve analysis: insights for clinical investigators","volume":"11","author":"Piovani","year":"2023","journal-title":"Healthcare (Basel)"},{"key":"B18","article-title":"Iodine-131 for therapy of thyroid diseases. Physical and biological basis","volume":"15","author":"Wyszomirska","year":"2012","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02573-1","article-title":"Predictive factors of a worse response to radioactive Iodine-I131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experience","volume":"73","author":"Finessi","year":"2021","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12902-020-00557-w","article-title":"Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves\u2019 disease patients","volume":"20","author":"Hu","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.14341\/probl12390","article-title":"Predictors of the efficacy of radioiodine therapy of Graves\u2019 disease in children and adolescents","volume":"66","author":"Rumyantsev","year":"2020","journal-title":"Probl Endokrinol (Mosk)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20191609","article-title":"Predictive factors for the outcomes of Graves\u2019 disease patients with radioactive iodine (131I) treatment","volume":"40","author":"Xing","year":"2020","journal-title":"Biosci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-018-0080-0","article-title":"Biological clocks: their relevance to immune-allergic diseases","volume":"16","author":"Paganelli","year":"2018","journal-title":"Clin Mol Allergy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-011-1053-z","article-title":"Sleep and metabolic function","volume":"463","author":"Morselli","year":"2012","journal-title":"Pflugers Arch"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00367","article-title":"Corticosteroid pulse therapy for Graves\u2019 Ophthalmopathy reduces the relapse rate of Graves\u2019 Hyperthyroidism","volume":"11","author":"Le Moli","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0484-y","article-title":"Relation between therapy options for Graves\u2019 disease and the course of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952954","article-title":"Research progress on the pathogenesis of Graves\u2019 ophthalmopathy: Based on immunity, noncoding RNA and exosomes","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0279-9","article-title":"The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy","volume":"33","author":"Huang","year":"2019","journal-title":"Eye (Lond)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0320(19970615)30:3<118::aid-cyto2>3.0.co;2-h","article-title":"Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves disease: relationship with disease activity","volume":"30","author":"Corrales","year":"1997","journal-title":"Cytometry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1677\/joe.1.06137","article-title":"Integrative study of hypothalamus-pituitary-thyroid-immune system interaction: thyroid hormone-mediated modulation of lymphocyte activity through the protein kinase C signaling pathway","volume":"189","author":"Klecha","year":"2006","journal-title":"J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7354673","article-title":"Thyroid isthmus length and iodine turnover as predictors of successful radioactive iodine therapy in patients with Graves\u2019 Disease","volume":"2017","author":"Park","year":"2017","journal-title":"Int J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e3182817c78","article-title":"High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover","volume":"38","author":"de Jong","year":"2013","journal-title":"Clin Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14130","article-title":"Diagnostic testing for Graves\u2019 or non-Graves\u2019 hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography","volume":"92","author":"Scappaticcio","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.12122\/j.issn.1673-4254.2022.11.05","article-title":"Value of thyroid 99mTcO4- imaging ROI ratio for estimating 131I dose in individualized treatment of hyperthyroidism","volume":"42","author":"Qi","year":"2022","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/er.2012-1030","article-title":"Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome","volume":"33","author":"Bonnema","year":"2012","journal-title":"Endocr Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/BF01323597","article-title":"Radioiodine: biokinetics, mean dose and dose distribution","volume":"18","author":"Kaul","year":"1980","journal-title":"Radiat Environ Biophys"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002191","article-title":"Nomogram for predicting severe abdominal adhesions prior to definitive surgery in patients with anastomotic fistula post-small intestine resection: a cohort study","volume":"111","author":"Yao","year":"2025","journal-title":"Int J Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000376","article-title":"Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study","volume":"109","author":"Deng","year":"2023","journal-title":"Int J Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002235","article-title":"Developing predictive nomogram models using quantitative electroencephalography for brain function in type a aortic dissection: a prospective observational study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.938290","article-title":"Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation","volume":"122","author":"Ferreira-Gonz\u00e1lez","year":"2010","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2018.10.036","article-title":"Analysis of the first 2645 registrations at the research registry\u00ae: A global repository for all study types involving human participants","volume":"60","author":"Fowler","year":"2018","journal-title":"Int J Surg"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1628226\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:15:45Z","timestamp":1755058545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1628226\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":41,"alternative-id":["10.3389\/fendo.2025.1628226"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1628226","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1628226"}}